Gilead Sciencesvs.Incyte
GILD vs INCY · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 7.0× larger than Incyte by market cap; year to date, Incyte leads (+29.6% vs +19.6%).
Side by side
| GILD | INCY | |
|---|---|---|
| Market cap | $170B | $24.4B |
| Price | $148.77 | $129.72 |
| Today | +1.4% | +1.4% |
| Return YTD | +19.6% | +29.6% |
| Return 1Y | +27.9% | +50.5% |
| P/E | — | 15.1 |
| P/S | 5.6 | 4.2 |
| P/B | 14.4 | 3.8 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →More GILD & INCY comparisons
Other head-to-heads in the Biotech & innovation segment.
See where GILD and INCY sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →